Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-04 · 398 (4) · 4019-4036
DOI: 10.1007/s00210-024-03496-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 15.10.2024. Verfasst von Reda A A Abo-Elsoud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Physiology Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt. Hauptthemen laut MEDLINE: Sirtuin 1, NF-kappa B, Multiple Sclerosis, Neuroprotective Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minufiya University.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a demyelinating disease affecting the central nervous system associated with progressive neurodegeneration. Pirfenidone (Pir) is a well-known antifibrotic agent; however, Pir’s function in MS is little explored. We evaluated the neuroprotective effects of Pir in MS and its possible underlying mechanisms. Forty male Swiss mice were divided equally into control, cuprizone (CPZ), Pir, and CPZ + Pir groups. Assessment of motor function was conducted using neurobehavioral tests, EMG, and nerve conduction velocity (NCV). Mice’s brains were extracted to measure oxidative stress, neuroinflammatory markers, and the expression of neurotrophic genes. The corpus callosum and the sciatic nerve were subjected to histopathological and immunohistochemical studies. The CPZ group was associated with significant reductions in muscle power, frequency of contraction, sciatic NCV, SOD, IL-10, SIRT1, NGF, and neuregulin-1. Significant increases in MDA, TNF-α, INF-γ, IL-17, TGF-β, and NF-κB were also detected. Multiple areas of partially demyelinated nerve fibers in the corpus callosum, the loss of oligodendrocyte nuclei, and increased microglia and astrocytes were also observed. The sciatic nerve revealed partial demyelination with significantly reduced myelin basic protein (MBP) expression. Pir significantly restored motor function, demyelination, and neurodegenerative changes induced by CPZ. Besides the antifibrotic action of Pir, we concluded that it improves motor function in MS by alleviating the demyelinating process and neurodegeneration. Its potential anti-inflammatory, antioxidant, and antifibrotic properties could be contributing factors. These effects could be mediated by modulating the NF-κB, SIRT1, NGF, and neuregulin-1 pathways. Pir is a promising agent for treating MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Physiology Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt.
- Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt.
- Anatomy and Embryology Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt.
- Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt.
- Medical Biochemistry and Molecular Biology Department, Faculty of Dentistry, AlRyada University, Sadat City, Menoufia, Egypt.
- Neuropsychiatry Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt.
ORCID-Profile: Reda A A Abo-Elsoud, Eman A Ali, Marwa A Al-Gholam, Mohamed S Rizk, Rasha S A Elseadawy, Omnia Ameen
Förderung
- Minufiya University
Zitieren
APA
Abo-Elsoud, R. A. A., Ali, E. A., Al-Gholam, M. A., Rizk, M. S., Elseadawy, R. S. A., & Ameen, O. (2025). Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(4), 4019-4036. https://doi.org/10.1007/s00210-024-03496-8
Vancouver
Abo-Elsoud RAA, Ali EA, Al-Gholam MA, Rizk MS, Elseadawy RSA, Ameen O. Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(4):4019-4036. doi:10.1007/s00210-024-03496-8
BibTeX
@article{AboElsoud2025,
author = {Abo-Elsoud, Reda A A and Ali, Eman A and Al-Gholam, Marwa A and Rizk, Mohamed S and Elseadawy, Rasha S A and Ameen, Omnia},
title = {Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {4},
pages = {4019--4036},
doi = {10.1007/s00210-024-03496-8}
}
EUVIMED